CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
2020
1.1K+
LTM Revenue $507M
LTM EBITDA $203M
$269M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CureVac has a last 12-month revenue of $507M and a last 12-month EBITDA of $203M.
In the most recent fiscal year, CureVac achieved revenue of $53.8M and an EBITDA of -$234M.
CureVac expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See CureVac valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $67.4M | $53.8M | $536M | $507M | XXX |
Gross Profit | -$135M | -$117M | -$70.6M | XXX | XXX |
Gross Margin | -201% | -217% | -13% | XXX | XXX |
EBITDA | -$222M | -$234M | $231M | $203M | XXX |
EBITDA Margin | -329% | -435% | 43% | 40% | XXX |
Net Profit | -$412M | -$249M | -$260M | XXX | XXX |
Net Margin | -611% | -463% | -49% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, CureVac's stock price is $4.
CureVac has current market cap of $803M, and EV of $269M.
See CureVac trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$269M | $803M | XXX | XXX | XXX | XXX | $0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, CureVac has market cap of $803M and EV of $269M.
CureVac's trades at 0.6x LTM EV/Revenue multiple, and 1.4x LTM EBITDA.
Analysts estimate CureVac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CureVac and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $269M | XXX | XXX | XXX |
EV/Revenue | 0.5x | XXX | XXX | XXX |
EV/EBITDA | 1.2x | XXX | XXX | XXX |
P/E | 4.2x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCureVac's NTM/LTM revenue growth is -85%
CureVac's revenue per employee for the last fiscal year averaged $48K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, CureVac's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CureVac's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CureVac and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 897% | XXX | XXX | XXX | XXX |
EBITDA Margin | 43% | XXX | XXX | XXX | XXX |
EBITDA Growth | -199% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -42% | XXX | XXX | XXX | XXX |
Revenue per Employee | $48K | XXX | XXX | XXX | XXX |
Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 141% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 215% | XXX | XXX | XXX | XXX |
Opex to Revenue | 383% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
CSL | XXX | XXX | XXX | XXX | XXX | XXX |
Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CureVac acquired XXX companies to date.
Last acquisition by CureVac was XXXXXXXX, XXXXX XXXXX XXXXXX . CureVac acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was CureVac founded? | CureVac was founded in 2020. |
Where is CureVac headquartered? | CureVac is headquartered in United States of America. |
How many employees does CureVac have? | As of today, CureVac has 1.1K+ employees. |
Who is the CEO of CureVac? | CureVac's CEO is Dr. Alexander Zehnder, M.B.A.,M.D.. |
Is CureVac publicy listed? | Yes, CureVac is a public company listed on NAS. |
What is the stock symbol of CureVac? | CureVac trades under CVAC ticker. |
When did CureVac go public? | CureVac went public in 2020. |
Who are competitors of CureVac? | Similar companies to CureVac include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
What is the current market cap of CureVac? | CureVac's current market cap is $803M |
What is the current revenue of CureVac? | CureVac's last 12-month revenue is $507M. |
What is the current EBITDA of CureVac? | CureVac's last 12-month EBITDA is $203M. |
What is the current EV/Revenue multiple of CureVac? | Current revenue multiple of CureVac is 0.6x. |
What is the current EV/EBITDA multiple of CureVac? | Current EBITDA multiple of CureVac is 1.4x. |
What is the current revenue growth of CureVac? | CureVac revenue growth between 2023 and 2024 was 897%. |
Is CureVac profitable? | Yes, CureVac is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.